Targeted Therapy

The advent of novel therapies has propelled, and continues to propel, tremendous progress and innovation in diffuse large B-cell lymphoma.

CHICAGO — Healio spoke with Nikhil Wagle, MD, about his educational session on the role genomic profiling and treatment decisions in metastatic breast cancer at ASCO Annual Meeting.

The development of targeted cancer therapies has led to improved clinical outcomes for many patients. However, monotherapies against a single target can result in treatment resistance.

CHICAGO — David Andrew Sallman, MD, myeloid section head at Moffitt Cancer Center, talked about two presentations on molecular targeted therapy from the ASCO Annual Meeting.

CHICAGO — In a video interview, Healio spoke with David Andrew Sallman, MD, myeloid section head at Moffitt Cancer Center, about using targeted therapy in patients with myelodysplastic syndrome at ASCO Annual Meeting.

NEW ORLEANS — There is no single answer when it comes to determining the primary target for treating type 2 diabetes, two speakers said during a debate at the American Diabetes Association Scientific Sessions.

Liquid biopsy — once just a promising technology — is now an important tool for selecting treatment for certain patients with breast cancer, according to Melissa McShane, MD.

In this video, Debu Tripathy, MD, discussed developments in HER2-positive breast cancer targeted treatments, including antibody-drug conjugates, which were reviewed at 39th Miami Breast Cancer Conference.

In this video, Stan Lipkowitz, MD, PhD, chief of the women's malignancies branch in the National Cancer Institute's Center for Cancer Research, discusses new research into targeting protein degradation.

Targeted therapies in HER2-positive breast cancer are integral to the success of treatment outcomes in this patient population.